RTS Life Science has supplied an Automated Liquid Store (ALS) to Glaxosmithkline (GSK), with an overview of the benefits detailed on a poster.
Since implementation, a System Development Programme, now in its third year of operation, has been adopted to provide support for GSK's day-to-day running as well as enhancements in terms of throughput, quality and maintenance.
The ALS operates in the company's high-throughput screening environment to increase throughput and capacity and to improve the efficiency and safety of its ALS processes, equipment and personnel.
The system has constantly evolved to cope with a continuous increase in demand for screening plates and the growth of the screening collection.
A poster, authored by GSK's ultra-high-throughput screening facilities group in Tres Cantos, Spain, and Collegeville, Pennsylvania, entitled 'Streamlining an Automated Liquid Store', was presented at the Society for Biomolecular Sciences' annual conference in Lille, and describes some of the enhancements and functionality added to the system to keep pace with GSK requirements.
A copy of the poster is available to download from the RTS Life Science website.
Collaboration between GSK and RTS has facilitated improvements that add value and functionality to the system while optimising the quality of the GSK compound collection to speed the drug discovery process.
Since implementing the RTS ALS, GSK has enabled the storage of more than two million compounds, in addition to the supply of more than 500,000 compounds daily in miniaturised format.
The system is driven by robotics software created by RTS Life Science and is constantly being developed to accommodate the demand for screening plates and the growth of the screening collection: from 17 million wells dispensed in 2004 to more than 70 million wells in 2009.
The poster outlines improvements across the GSK ALS and presents an overview of the benefits achieved.
